Journal of Drugs in Dermatology
Journal of Drugs in Dermatology (JDD) is a peer-reviewed medical journal that publishes articles related to the field of dermatology. The journal focuses on providing information about the latest advancements in dermatological drugs, therapies, and treatments.
Overview[edit | edit source]
The Journal of Drugs in Dermatology (JDD) is a bimonthly, peer-reviewed publication that was founded in 2002. It is dedicated to providing dermatologists and other medical professionals with the most up-to-date information on drugs, devices, and therapies in the field of dermatology. The journal is indexed in PubMed, MEDLINE, and Embase, among other databases.
Content[edit | edit source]
The JDD publishes original articles, case reports, product reviews, and clinical trials. The journal's content is divided into several sections, including:
- Clinical Trials: This section features reports on the latest clinical trials in dermatology.
- Case Reports: This section includes detailed reports on unique or interesting patient cases.
- Reviews: This section provides comprehensive reviews of current topics in dermatology.
- Product Reviews: This section offers evaluations of dermatological products and devices.
Editorial Board[edit | edit source]
The JDD's editorial board is composed of leading experts in the field of dermatology. The board is responsible for reviewing submissions and ensuring the quality of the journal's content.
Abstracting and Indexing[edit | edit source]
The Journal of Drugs in Dermatology is abstracted and indexed in several databases, including PubMed, MEDLINE, and Embase. This ensures that the journal's articles are easily accessible to researchers and medical professionals worldwide.
See Also[edit | edit source]
| Journal of Drugs in Dermatology Resources | ||
|---|---|---|
|
| |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
